The potential reassessment of cannabinoids, particularly at the federal level, is generating considerable buzz within the industry. A shift away from Schedule I status, often regarded as outdated and hindering innovation, could unlock significant avenues for ventures. Reduced regulatory burdens, alongside greater access to banking and capital, are